Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS)

Schizophrenia Research
Keith H NuechterleinDavid L Braff

Abstract

Attention/vigilance impairments are present in individuals with schizophrenia across psychotic and remitted states and in their first-degree relatives. An important question is whether deficits in attention/vigilance can be consistently and reliably measured across sites varying in many participant demographic, clinical, and functional characteristics, as needed for large-scale genetic studies of endophenotypes. We examined Continuous Performance Test (CPT) data from phase 2 of the Consortium on the Genetics of Schizophrenia (COGS-2), the largest-scale assessment of cognitive and psychophysiological endophenotypes relevant to schizophrenia. The CPT data from 2251 participants from five sites were examined. A perceptual-load vigilance task (the Degraded Stimulus CPT or DS-CPT) and a memory-load vigilance task (CPT-Identical Pairs or CPT-IP) were utilized. Schizophrenia patients performed more poorly than healthy comparison subjects (HCS) across sites, despite significant site differences in participant age, sex, education, and racial distribution. Patient-HCS differences in signal/noise discrimination (d') in the DS-CPT varied significantly across sites, but averaged a medium effect size. CPT-IP performance showed large patient-...Continue Reading

References

Sep 1, 1992·Progress in Neuro-psychopharmacology & Biological Psychiatry·W MaierF Rist
May 1, 1991·Journal of Abnormal Psychology·W M GroveW G Iacono
Jan 1, 1986·Schizophrenia Bulletin·K H NuechterleinM E Dawson
Apr 1, 1973·Archives of General Psychiatry·G W Wohlberg, C Kornetsky
Jul 1, 1984·British Journal of Pharmacology·F Andreasen, J H Christensen
May 1, 1995·Psychosomatics·R C Hall
May 1, 1995·Archives of General Psychiatry·N C AndreasenM Flaum
Jan 1, 1994·Schizophrenia Bulletin·B A Cornblatt, J G Keilp
Jan 1, 1993·Schizophrenia Bulletin·D L Braff
Apr 1, 1993·Community Mental Health Journal·S H GoodmanN Leavitt
Jul 23, 1998·Neuropsychology·R W Heinrichs, K K Zakzanis
Feb 29, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·S K LiuH N Lin
Jul 27, 2000·The American Journal of Psychiatry·M F EganD R Weinberger
Nov 22, 2000·Schizophrenia Bulletin·M SaoudT Rochet
Apr 11, 2001·Schizophrenia Research·L A JonesJ Williams
Jun 27, 2001·American Journal of Medical Genetics·B A Cornblatt, A K Malhotra
Aug 2, 2002·Journal of Abnormal Psychology·Deanna M BarchAbraham Z Snyder
Apr 2, 2003·The American Journal of Psychiatry·Irving I Gottesman, Todd D Gould
Sep 6, 2003·Schizophrenia Research·Melanie C M AppelsRené S Kahn
Oct 1, 1956·Journal of Consulting Psychology·L H BECKI SARASON
May 4, 2004·Biological Psychiatry·Wei J ChenUNKNOWN Multidimensional Psychopathology Group Research Project
Nov 9, 2004·Schizophrenia Research·Keith H NuechterleinRobert K Heaton
Jun 11, 2008·Archives of Internal Medicine·Séverine SabiaArchana Singh-Manoux
Mar 23, 2011·Schizophrenia Research·Rachel A RabinTony P George
Mar 21, 2013·The American Journal of Psychiatry·Tiffany A GreenwoodDavid L Braff
Jun 29, 2013·The American Journal on Addictions·Samuel R ChamberlainJon E Grant
Jul 31, 2013·Psychiatry and Clinical Neurosciences·Patrizia Thoma, Irene Daum
Oct 18, 2013·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Wei J Chen

❮ Previous
Next ❯

Citations

Sep 13, 2015·Current Opinion in Neurobiology·Winifred Mark, Timothea Toulopoulou
Nov 30, 2014·Schizophrenia Research·Ruben C GurRaquel E Gur
Jun 18, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Andrea SchmittUNKNOWN WFSBP Task Force on Biological Markers
Sep 14, 2016·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·Beatriz López-LuengoMiguel García-Cobo
Jul 15, 2015·Journal of Psychopharmacology·Adam Michael StewartAllan V Kalueff
Jan 28, 2017·Neuropsychologia·Megan A BoudewynTamara Y Swaab
Dec 8, 2017·The Clinical Neuropsychologist·Saima SaleemGanesan Venkatasubramanian
Nov 2, 2017·Annals of the New York Academy of Sciences·Marc HoonakkerAnne Bonnefond
May 16, 2019·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·M M PopovV G Kaleda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.